\-\ Texto\\:\\ \ \(0\)\
\-\ labs\\/pe\\:\\ \\ slight\\ antalgic\\ gait\\ on\\ the\\ right\\.\\ \\ muscle\\ strength\\ 5\\/5\\ with\\ 2\\+\\ deep\\ tendon\\ reflexes\\ bilaterally\\.\\ \\ pulses\\ normal\\ in\\ dorsal\\ pedis\\,\\ posterior\\ tibial\\ and\\ femoral\\ arteries\\.\ \(0\)\
\-\ ldh\\ 574\\ u\\/l\\ \\(313\\-618\\)\ \(0\)\
\-\ alpha\\ fetoprotein\\ \\(3\\/1\\/05\\)\\ 243\\.1\\ ng\\/ml\\ \\(0\\.0\\ \\â\\€\\“\\ 15\\.0\\)\\ \\ \ \(0\)\
\-\ alpha\\ fetoprotein\\ \\(1\\/7\\/05\\)\\ 46\\.1\\ ng\\/ml\\ \\(0\\.0\\ \\â\\€\\“\\ 15\\.0\\)\\ \\ \ \(0\)\
\-\ alpha\\ fetoprotein\\ \\(12\\/29\\/04\\)\\ 38\\.7\\ ng\\/ml\\ \\(0\\.0\\ \\â\\€\\“\\ 15\\.0\\)\\ \\ \ \(0\)\
\-\ initial\\ pathology\\ \\(percutaneous\\ biopsy\\)\\:\ \(0\)\
\-\ bone\\ and\\ soft\\ tissue\\ reaming\\,\\ right\\ femur\\:\ \(0\)\
\-\ devitalized\\ bone\\,\\ necrotic\\ and\\ viable\\ hematopoietic\\ bone\\ marrow\\ with\\ no\\ evidence\\ of\\ malignancy\ \(0\)\
\-\ re\\-biopsy\\ result\\:\ \(0\)\
\-\ metastatic\\ hepatocellular\\ carcinoma\\.\ \(0\)\
\-\ patient\\ underwent\\ orif\\ of\\ the\\ right\\ femur\\ by\\ orthopedic\\ surgery\\.\\ \\ following\\ the\\ surgical\\ procedure\\,\\ the\\ patient\\ proceeded\\ to\\ undergo\\ prophylactic\\ palliative\\ radiation\\ therapy\\ to\\ the\\ left\\ hip\\,\\ which\\ was\\ followed\\ by\\ palliative\\ radiation\\ therapy\\ to\\ the\\ right\\ humerus\\ and\\ right\\ postoperative\\ hip\\/femur\\.the\\ patient\\ tolerated\\ radiation\\ therapy\\ well\\ with\\ amelioration\\ of\\ his\\ right\\ humerus\\ pain\\ by\\ the\\ completion\\ of\\ therapy\\ and\\ decrease\\ in\\ his\\ right\\ hip\\ pain\\,\\ as\\ well\\.\ \(0\)\
\-\ ap\\ radiograph\\ of\\ the\\ hips\\ demontrate\\ a\\ poorly\\ defined\\ lucency\\ of\\ the\\ greater\\ trochanter\\ and\\ intertrochanteric\\ region\\ extending\\ into\\ the\\ femoral\\ neck\\.\ \(0\)\
\-\ ct\\ demonstrates\\ a\\ lytic\\ lesion\\ in\\ the\\ right\\ femoral\\ neck\\ with\\ thinning\\ of\\ the\\ cortex\\ and\\ destruction\\ of\\ the\\ anterior\\ cortex\\.\ \(0\)\
\-\ mri\\ demonstrates\\ a\\ 3\\ cm\\ circumscribed\\ lesion\\ in\\ the\\ anterior\\ right\\ femoral\\ neck\\.\\ \\ low\\ signal\\ on\\ t1\\ and\\ moderately\\ high\\ on\\ t2\\ with\\ moderate\\ enhancement\\ with\\ surrounding\\ edema\\.\\ \\ a\\ second\\ lesion\\ is\\ at\\ the\\ base\\ of\\ the\\ lesser\\ trochanter\\ measuring\\ 1\\.8\\ cm\ \(0\)\
\-\ fdg\\ pet\\ scan\\ demonstrates\\ \\ focal\\ areas\\ of\\ increased\\ metabolism\\ in\\ the\\ left\\ and\\ right\\ femoral\\ neck\\.\\ \\ focal\\ area\\ of\\ photopenia\\ in\\ the\\ right\\ lobe\\ of\\ the\\ liver\\ is\\ demonstrated\\ compatible\\ with\\ patient\\'s\\ prior\\ chemoembolization\\ of\\ hepatocellular\\ carcinoma\\.\ \(0\)\
\-\ focal\\ increased\\ metabolism\\ in\\ the\\ femoral\\ necks\\ extending\\ into\\ the\\ femoral\\ heads\\.\\ \\ suv\\ value\\ in\\ the\\ right\\ femoral\\ head\\ is\\ 2\\.29\\ and\\ in\\ the\\ left\\ femoral\\ head\\ of\\ 3\\.21\\.\ \(0\)\
\-\ hepatocellular\\ carcinoma\\ and\\ bone\\ metastasis\\.\ \(0\)\
\-\ metastatic\\ disease\ \(243\)\
\-\ infection\ \(713\)\
\-\ primary\\ neoplasm\ \(4\)\
\-\ 38\\-year\\-old\\ nigerian\\ male\\ was\\ diagnosed\\ with\\ hepatocellular\\ carcinoma\\ in\\ july\\ 2004\\.\\ thereafter\\,\\ heunderwent\\ multiple\\ chemoembolizations\\ of\\ liver\\ metastases\\ for\\ his\\ disease\\,\\ as\\ well\\ as\\ multiple\\ agent\\ narcotic\\ analgesia\\ for\\ pain\\ control\\.\\ he\\ noted\\ right\\ hip\\ pain\\ and\\ difficulty\\ ambulating\\ for\\ 4\\ weeks\\.\\ \\ patient\\ just\\ underwent\\ chemoembolization\\ for\\ a\\ lesion\\ in\\ the\\ left\\ lobe\\ of\\ the\\ liver\\.\ \(0\)\
\-\ in\\ the\\ setting\\ of\\ hepatocellular\\ carcinoma\\,\\ a\\ lytic\\ lesion\\ must\\ be\\ presumed\\ to\\ be\\ metastatic\\ in\\ nature\\.\\ \\ furthermore\\,\\ hepatocellular\\ carcinoma\\ must\\ be\\ excluded\\ in\\ a\\ patient\\ with\\ a\\ lytic\\ bone\\ lesion\\ in\\ a\\ patient\\ with\\ a\\ history\\ of\\ cirrhosis\\.\\ \\ risk\\ factors\\ for\\ bone\\ metastasis\\ in\\ this\\ patient\\ included\\ multifocal\\ hepatocellular\\ carcinoma\\ and\\ rising\\ alpha\\ fetoprotein\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ hepatocellular\\:\\ 0\\.07271284152107826\ \(0\)\
\-\ femoral\\:\\ 0\\.061727810442603885\ \(0\)\
\-\ fetoprotein\\:\\ 0\\.05797137784735176\ \(0\)\
\-\ 15\\.0\\:\\ 0\\.055794420404851254\ \(0\)\
\-\ alpha\\:\\ 0\\.04830781409795934\ \(0\)\
\-\ 0\\.0\\:\\ 0\\.04702040546105448\ \(0\)\
\-\ ng\\/ml\\:\\ 0\\.03594952030403385\ \(0\)\
\-\ carcinoma\\:\\ 0\\.03576686432512883\ \(0\)\
\-\ chemoembolization\\:\\ 0\\.032560785381005854\ \(0\)\
\-\ trochanter\\:\\ 0\\.02707857869691193\ \(0\)\
\-\ bone\\:\\ 0\\.026878920018479364\ \(0\)\
\-\ right\\:\\ 0\\.024728295819484002\ \(0\)\
\-\ \\â\\€\\“\\:\\ 0\\.02433990585057277\ \(0\)\
\-\ lytic\\:\\ 0\\.024209404032833934\ \(0\)\
\-\ metabolism\\:\\ 0\\.023449037493438882\ \(0\)\
\-\ lesion\\:\\ 0\\.022032344632917148\ \(0\)\
\-\ palliative\\:\\ 0\\.021960339710220562\ \(0\)\
\-\ hip\\:\\ 0\\.02154349602602189\ \(0\)\
\-\ neck\\:\\ 0\\.02117504756977622\ \(0\)\
\-\ therapy\\:\\ 0\\.01927966916658745\ \(0\)\
\-\ liver\\:\\ 0\\.018646971587548883\ \(0\)\
\-\ labs\\/pe\\:\\ 0\\.018598140134950418\ \(0\)\
\-\ 574\\:\\ 0\\.018598140134950418\ \(0\)\
\-\ 3\\/1\\/05\\:\\ 0\\.018598140134950418\ \(0\)\
\-\ 243\\.1\\:\\ 0\\.018598140134950418\ \(0\)\
\-\ 1\\/7\\/05\\:\\ 0\\.018598140134950418\ \(0\)\
\-\ 46\\.1\\:\\ 0\\.018598140134950418\ \(0\)\
\-\ 12\\/29\\/04\\:\\ 0\\.018598140134950418\ \(0\)\
\-\ reaming\\:\\ 0\\.018598140134950418\ \(0\)\
\-\ devitalized\\:\\ 0\\.018598140134950418\ \(0\)\
\-\ re\\-biopsy\\:\\ 0\\.018598140134950418\ \(0\)\
\-\ hip\\/femur\\.the\\:\\ 0\\.018598140134950418\ \(0\)\
\-\ 2\\.29\\:\\ 0\\.018598140134950418\ \(0\)\
\-\ 3\\.21\\.\\:\\ 0\\.018598140134950418\ \(0\)\
\-\ heunderwent\\:\\ 0\\.018598140134950418\ \(0\)\
\-\ chemoembolizations\\:\\ 0\\.018598140134950418\ \(0\)\
\-\ humerus\\:\\ 0\\.018551383190590295\ \(0\)\
\-\ radiation\\:\\ 0\\.017748425630141368\ \(0\)\
\-\ 38\\.7\\:\\ 0\\.017135804310984288\ \(0\)\
\-\ hematopoietic\\:\\ 0\\.017135804310984288\ \(0\)\
\-\ nigerian\\:\\ 0\\.017135804310984288\ \(0\)\
\-\ must\\:\\ 0\\.016436867080752628\ \(0\)\
\-\ 313\\-618\\:\\ 0\\.016280392690502927\ \(0\)\
\-\ amelioration\\:\\ 0\\.016280392690502927\ \(0\)\
\-\ 38\\-year\\-old\\:\\ 0\\.016280392690502927\ \(0\)\
\-\ demontrate\\:\\ 0\\.015673468487018158\ \(0\)\
\-\ narcotic\\:\\ 0\\.015673468487018158\ \(0\)\
\-\ his\\:\\ 0\\.015587905238271721\ \(0\)\
\-\ femur\\:\\ 0\\.01557617909098413\ \(0\)\
\-\ focal\\:\\ 0\\.015446162051508873\ \(0\)\
\-\ cortex\\:\\ 0\\.015428114450430248\ \(0\)\
\-\ necks\\:\\ 0\\.015202701501123201\ \(0\)\
\-\ pedis\\:\\ 0\\.01449284446183794\ \(0\)\
\-\ photopenia\\:\\ 0\\.01449284446183794\ \(0\)\
\-\ patient\\:\\ 0\\.014457247779179543\ \(0\)\
\-\ in\\:\\ 0\\.0142243790764643\ \(0\)\
\-\ analgesia\\:\\ 0\\.01396264524605544\ \(0\)\
\-\ metastatic\\:\\ 0\\.01361461647858285\ \(0\)\
\-\ intertrochanteric\\:\\ 0\\.013539289348455965\ \(0\)\
\-\ metastasis\\:\\ 0\\.013496824161603065\ \(0\)\
\-\ ambulating\\:\\ 0\\.013355721042570668\ \(0\)\
\-\ 2004\\.\\:\\ 0\\.013186854570685571\ \(0\)\
\-\ rising\\:\\ 0\\.013186854570685571\ \(0\)\
\-\ antalgic\\:\\ 0\\.0127487968390859\ \(0\)\
\-\ proceeded\\:\\ 0\\.0127487968390859\ \(0\)\
\-\ thereafter\\:\\ 0\\.0127487968390859\ \(0\)\
\-\ viable\\:\\ 0\\.012620896793059666\ \(0\)\
\-\ suv\\:\\ 0\\.012386243554430501\ \(0\)\
\-\ underwent\\:\\ 0\\.012372135170794173\ \(0\)\
\-\ well\\:\\ 0\\.012234689575750956\ \(0\)\
\-\ \\(\\:\\ 0\\.012191759092723383\ \(0\)\
\-\ extending\\:\\ 0\\.012121177421264966\ \(0\)\
\-\ completion\\:\\ 0\\.012076953524489835\ \(0\)\
\-\ \\)\\:\\ 0\\.01204283024663806\ \(0\)\
\-\ demonstrates\\:\\ 0\\.011814058238311304\ \(0\)\
\-\ orif\\:\\ 0\\.011724518746719441\ \(0\)\
\-\ fdg\\:\\ 0\\.011724518746719441\ \(0\)\
\-\ july\\:\\ 0\\.011644897801607951\ \(0\)\
\-\ 1\\.8\\:\\ 0\\.011568172813905682\ \(0\)\
\-\ agent\\:\\ 0\\.011568172813905682\ \(0\)\
\-\ tolerated\\:\\ 0\\.011353441391310868\ \(0\)\
\-\ ldh\\:\\ 0\\.01128646101511977\ \(0\)\
\-\ prophylactic\\:\\ 0\\.011097405828010725\ \(0\)\
\-\ lesser\\:\\ 0\\.011097405828010725\ \(0\)\
\-\ furthermore\\:\\ 0\\.01103797359812318\ \(0\)\
\-\ u\\/l\\:\\ 0\\.010980169855110281\ \(0\)\
\-\ heads\\:\\ 0\\.010923907730464371\ \(0\)\
\-\ thinning\\:\\ 0\\.010712761193424323\ \(0\)\
\-\ hips\\:\\ 0\\.010614617700523705\ \(0\)\
\-\ cirrhosis\\:\\ 0\\.010614617700523705\ \(0\)\
\-\ postoperative\\:\\ 0\\.010475465869739324\ \(0\)\
\-\ moderately\\:\\ 0\\.010303149348612177\ \(0\)\
\-\ head\\:\\ 0\\.010226165867400404\ \(0\)\
\-\ value\\:\\ 0\\.010221996857414296\ \(0\)\
\-\ presumed\\:\\ 0\\.010221996857414296\ \(0\)\
\-\ 5\\/5\\:\\ 0\\.010031804669662614\ \(0\)\
\-\ compatible\\:\\ 0\\.009960282408743455\ \(0\)\
\-\ necrotic\\:\\ 0\\.009857349572942965\ \(0\)\
\-\ excluded\\:\\ 0\\.009759206080042345\ \(0\)\
\-\ lobe\\:\\ 0\\.009701794716976936\ \(0\)\
\-\ multifocal\\:\\ 0\\.009696225145127408\ \(0\)\
\-\ cm\\:\\ 0\\.00967070091905901\ \(0\)\
\-\ percutaneous\\:\\ 0\\.009546537938434825\ \(0\)\
\-\ \\:\\:\\ 0\\.009538184101187046\ \(0\)\
\-\ pet\\:\\ 0\\.009461571906498243\ \(0\)\
\-\ pulses\\:\\ 0\\.009327150357160462\ \(0\)\
\-\ anterior\\:\\ 0\\.009286045669884967\ \(0\)\
\-\ 2\\+\\:\\ 0\\.00922545815923245\ \(0\)\
\-\ dorsal\\:\\ 0\\.009176393049181254\ \(0\)\
\-\ undergo\\:\\ 0\\.009152281876557576\ \(0\)\
\-\ setting\\:\\ 0\\.009104870788262096\ \(0\)\
\-\ by\\:\\ 0\\.009005512045853637\ \(0\)\
\-\ destruction\\:\\ 0\\.008903794459560988\ \(0\)\
\-\ increased\\:\\ 0\\.008820610893669433\ \(0\)\
\-\ pain\\:\\ 0\\.008806819979162318\ \(0\)\
\-\ poorly\\:\\ 0\\.008799847098787185\ \(0\)\
\-\ orthopedic\\:\\ 0\\.008606160286016882\ \(0\)\
\-\ into\\:\\ 0\\.008579436151728721\ \(0\)\
\-\ reflexes\\:\\ 0\\.008533404640297115\ \(0\)\
\-\ nature\\:\\ 0\\.008533404640297115\ \(0\)\
\-\ slight\\:\\ 0\\.008480438561961512\ \(0\)\
\-\ tendon\\:\\ 0\\.00841182423346877\ \(0\)\
\-\ gait\\:\\ 0\\.008395013748976835\ \(0\)\
\-\ a\\:\\ 0\\.008367084426552769\ \(0\)\
\-\ be\\:\\ 0\\.0083402324262274\ \(0\)\
\-\ tibial\\:\\ 0\\.008329080112892226\ \(0\)\
\-\ included\\:\\ 0\\.008312913714694824\ \(0\)\
\-\ lucency\\:\\ 0\\.008280947881318026\ \(0\)\
\-\ decrease\\:\\ 0\\.008249459167780734\ \(0\)\
\-\ control\\:\\ 0\\.008218433540376314\ \(0\)\
\-\ as\\:\\ 0\\.008180870290469162\ \(0\)\
\-\ factors\\:\\ 0\\.008098701859801527\ \(0\)\
\-\ left\\:\\ 0\\.008068398896817845\ \(0\)\
\-\ difficulty\\:\\ 0\\.008027179598882368\ \(0\)\
\-\ circumscribed\\:\\ 0\\.008013161576269141\ \(0\)\
\-\ strength\\:\\ 0\\.007999236082532113\ \(0\)\
\-\ marrow\\:\\ 0\\.007930954891599557\ \(0\)\
\-\ metastases\\:\\ 0\\.007701967194183511\ \(0\)\
\-\ for\\:\\ 0\\.007691014226188978\ \(0\)\
\-\ defined\\:\\ 0\\.007596165962779561\ \(0\)\
\-\ multiple\\:\\ 0\\.0075941181581403745\ \(0\)\
\-\ the\\:\\ 0\\.007583294097667238\ \(0\)\
\-\ procedure\\:\\ 0\\.007550794221807065\ \(0\)\
\-\ just\\:\\ 0\\.007528469096637156\ \(0\)\
\-\ arteries\\:\\ 0\\.007462877140793208\ \(0\)\
\-\ pathology\\:\\ 0\\.007378477700679919\ \(0\)\
\-\ deep\\:\\ 0\\.007297325209482036\ \(0\)\
\-\ measuring\\:\\ 0\\.007209611228794821\ \(0\)\
\-\ moderate\\:\\ 0\\.007089023857824465\ \(0\)\
\-\ base\\:\\ 0\\.007062148276015541\ \(0\)\
\-\ malignancy\\:\\ 0\\.00696643391941248\ \(0\)\
\-\ second\\:\\ 0\\.0069243226481834974\ \(0\)\
\-\ result\\:\\ 0\\.006916000331113842\ \(0\)\
\-\ greater\\:\\ 0\\.006771553497195149\ \(0\)\
\-\ diagnosed\\:\\ 0\\.0066291037063185764\ \(0\)\
\-\ ap\\:\\ 0\\.006593162383211893\ \(0\)\
\-\ risk\\:\\ 0\\.00652997182987149\ \(0\)\
\-\ muscle\\:\\ 0\\.006475348593726465\ \(0\)\
\-\ biopsy\\:\\ 0\\.00639597730303114\ \(0\)\
\-\ neoplasm\\:\\ 0\\.006139570835257232\ \(0\)\
\-\ areas\\:\\ 0\\.006066133272671026\ \(0\)\
\-\ followed\\:\\ 0\\.006044041922740023\ \(0\)\
\-\ initial\\:\\ 0\\.005973801990040733\ \(0\)\
\-\ surrounding\\:\\ 0\\.005926508996550137\ \(0\)\
\-\ bilaterally\\:\\ 0\\.00592131906861583\ \(0\)\
\-\ disease\\:\\ 0\\.005893407346901705\ \(0\)\
\-\ radiograph\\:\\ 0\\.005742507708694857\ \(0\)\
\-\ t1\\:\\ 0\\.005714125603848615\ \(0\)\
\-\ \\,\\:\\ 0\\.005711182816820409\ \(0\)\
\-\ area\\:\\ 0\\.005700076464418284\ \(0\)\
\-\ primary\\:\\ 0\\.005340473128471933\ \(0\)\
\-\ demonstrated\\:\\ 0\\.005289915574803728\ \(0\)\
\-\ infection\\:\\ 0\\.0052405412955122506\ \(0\)\
\-\ following\\:\\ 0\\.005116619740297781\ \(0\)\
\-\ weeks\\:\\ 0\\.005116619740297781\ \(0\)\
\-\ t2\\:\\ 0\\.0051025079509501095\ \(0\)\
\-\ edema\\:\\ 0\\.005098994703441541\ \(0\)\
\-\ region\\:\\ 0\\.0050919857114753424\ \(0\)\
\-\ scan\\:\\ 0\\.005046986203445102\ \(0\)\
\-\ he\\:\\ 0\\.005029931101335484\ \(0\)\
\-\ 4\\:\\ 0\\.005023147479280686\ \(0\)\
\-\ low\\:\\ 0\\.005013012769760336\ \(0\)\
\-\ and\\:\\ 0\\.004936955853415274\ \(0\)\
\-\ high\\:\\ 0\\.0049336414790650115\ \(0\)\
\-\ enhancement\\:\\ 0\\.004832254780850287\ \(0\)\
\-\ signal\\:\\ 0\\.004753321371883499\ \(0\)\
\-\ evidence\\:\\ 0\\.004726672116807758\ \(0\)\
\-\ prior\\:\\ 0\\.004628929899161104\ \(0\)\
\-\ on\\:\\ 0\\.0045815886858571395\ \(0\)\
\-\ of\\:\\ 0\\.004424194967012219\ \(0\)\
\-\ soft\\:\\ 0\\.004390140852307067\ \(0\)\
\-\ surgery\\:\\ 0\\.0043776351568782165\ \(0\)\
\-\ tissue\\:\\ 0\\.004273040481967497\ \(0\)\
\-\ noted\\:\\ 0\\.004273040481967497\ \(0\)\
\-\ 3\\:\\ 0\\.004221467355920969\ \(0\)\
\-\ was\\:\\ 0\\.004169947351112602\ \(0\)\
\-\ posterior\\:\\ 0\\.004155355587979849\ \(0\)\
\-\ mri\\:\\ 0\\.004141932183364176\ \(0\)\
\-\ \\'s\\:\\ 0\\.003974781895289124\ \(0\)\
\-\ surgical\\:\\ 0\\.0037894974055937836\ \(0\)\
\-\ to\\:\\ 0\\.003603950282219293\ \(0\)\
\-\ is\\:\\ 0\\.0035588023948400355\ \(0\)\
\-\ which\\:\\ 0\\.0033652839393302713\ \(0\)\
\-\ male\\:\\ 0\\.003259927295121251\ \(0\)\
\-\ normal\\:\\ 0\\.0028261866130782722\ \(0\)\
\-\ ct\\:\\ 0\\.0025217376653840565\ \(0\)\
\-\ history\\:\\ 0\\.002489904087989627\ \(0\)\
\-\ with\\:\\ 0\\.0024684425335419775\ \(0\)\
\-\ at\\:\\ 0\\.00244253829711315\ \(0\)\
\-\ this\\:\\ 0\\.002027715639903234\ \(0\)\
\-\ no\\:\\ 0\\.0018152830183624513\ \(0\)\
\-\ \\.\\:\\ 0\\.0014978707214070158\ \(0\)\
